Adalta Ltd Cash Flow Conversion Efficiency
Adalta Ltd cash flow conversion efficiency. Based on the latest financial reports, Adalta Ltd (1AD) has a cash flow conversion efficiency ratio of 2.240x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-489.87K ≈ $-346.61K USD) by net assets (AU$-218.66K ≈ $-154.71K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Adalta Ltd (2013–2025)
Cash flow conversion efficiency of Adalta Ltd from 2013 to 2025. This chart illustrates how Adalta Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Adalta Ltd (1AD) stock price for real-time trading data and today's change.
Adalta Ltd Cash Flow Conversion Ratio Explained
Adalta Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Adalta Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adalta Ltd ranked by their cash flow conversion efficiency. Also see 1AD stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Intelicanna Ltd
TA:INTL
|
-0.023x |
|
Biofil Chemicals & Pharmaceuticals Limited
NSE:BIOFILCHEM
|
-0.167x |
|
Nandani Creation Limited
NSE:JAIPURKURT
|
-0.166x |
|
Gaxos.ai Inc
NASDAQ:GXAI
|
-0.067x |
|
TruCap Finance Limited
NSE:TRU
|
1.175x |
|
Bulletin Resources Ltd
AU:BNR
|
-0.046x |
|
Balkrishna Paper Mills Limited
NSE:BALKRISHNA
|
0.020x |
|
Ambertech Ltd
AU:AMO
|
-0.183x |
Annual Cash Flow Conversion Efficiency for Adalta Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Adalta Ltd from 2013 to 2025. Review cash generation quality of Adalta Ltd to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$-598.24K ≈ $-423.30K |
AU$-2.94 Million ≈ $-2.08 Million |
4.909x | +289.49% |
| 2024-06-30 | AU$2.03 Million ≈ $1.44 Million |
AU$-5.26 Million ≈ $-3.72 Million |
-2.590x | +3.59% |
| 2023-06-30 | AU$1.91 Million ≈ $1.35 Million |
AU$-5.13 Million ≈ $-3.63 Million |
-2.687x | -253.48% |
| 2022-06-30 | AU$5.38 Million ≈ $3.81 Million |
AU$-4.09 Million ≈ $-2.89 Million |
-0.760x | -1.52% |
| 2021-06-30 | AU$6.39 Million ≈ $4.52 Million |
AU$-4.78 Million ≈ $-3.38 Million |
-0.749x | +52.93% |
| 2020-06-30 | AU$3.70 Million ≈ $2.62 Million |
AU$-5.89 Million ≈ $-4.17 Million |
-1.591x | -104.89% |
| 2019-06-30 | AU$7.49 Million ≈ $5.30 Million |
AU$-5.82 Million ≈ $-4.12 Million |
-0.776x | +19.51% |
| 2018-06-30 | AU$4.07 Million ≈ $2.88 Million |
AU$-3.93 Million ≈ $-2.78 Million |
-0.965x | -100.48% |
| 2017-06-30 | AU$7.75 Million ≈ $5.48 Million |
AU$-3.73 Million ≈ $-2.64 Million |
-0.481x | -334.96% |
| 2016-06-30 | AU$10.62 Million ≈ $7.51 Million |
AU$-1.17 Million ≈ $-830.93K |
-0.111x | +94.35% |
| 2015-06-30 | AU$705.89K ≈ $499.46K |
AU$-1.38 Million ≈ $-978.16K |
-1.958x | +73.76% |
| 2014-06-30 | AU$172.82K ≈ $122.28K |
AU$-1.29 Million ≈ $-912.79K |
-7.465x | -219.41% |
| 2013-06-30 | AU$283.92K ≈ $200.89K |
AU$-663.54K ≈ $-469.50K |
-2.337x | -- |
About Adalta Ltd
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age… Read more